Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

A potential therapeutic role for immune transformation in Parkinson’s disease evolves from more than a decade of animal investigations demonstrating regulatory T cell (Treg) nigrostriatal neuroprotection. To bridge these results to human disease, we conducted a randomized, placebo-controlled double-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gendelman, Howard E., Zhang, Yuning, Santamaria, Pamela, Olson, Katherine E., Schutt, Charles R., Bhatti, Danish, Shetty, Bhagya Laxmi Dyavar, Lu, Yaman, Estes, Katherine A., Standaert, David G., Heinrichs-Graham, Elizabeth, Larson, LuAnn, Meza, Jane L., Follett, Matthew, Forsberg, Erica, Siuzdak, Gary, Wilson, Tony W., Peterson, Carolyn, Mosley, R. Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445595/
https://www.ncbi.nlm.nih.gov/pubmed/28649610
http://dx.doi.org/10.1038/s41531-017-0013-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445595/
https://www.ncbi.nlm.nih.gov/pubmed/28649610
http://dx.doi.org/10.1038/s41531-017-0013-5

Ejemplares similares